Join the Oncology Voice Network. Join for Free
How will COVID-19 affect the MSL role and what new skills may emerge as necessary to maintain value, access and future succes
Paul Ward Oncology MSLs AstraZeneca MSL Society Covid-19 impact on MSLs

How will COVID-19 affect the MSL role and what new skills may emerge as necessary to maintain value, access and future succes


Share This Article


Summary

My guest today is Paul Ward. He is the National Director, Oncology MSLs at AstraZeneca, and MSL Society Advisory Board Member. We will discuss how Covid-19 will affect the role of the MSL and what new skills may emerge as necessary to maintain value, access, and future success.

In this episode:

  • How interviews are being conducted during this time
  • Considering the travel bans and limited access, what other activities should MSLs be focusing on during the pandemic?
  • Skills mandatory for MSLs during and after the crisis to find success
  • How has COVID 19 affected the hiring landscape and what is expected to happen in the upcoming months/year
  • How will HCP expectations change as a result of Covid
  • How an MSL can meet or exceed expectations during the pandemic
  • How does Paul expect Pharma to change practices as a result of Covid-19
  • The advice Paul can give to MSLs to help aid in their success

Click for Source
Paul Ward, Oncology MSLs, AstraZeneca, MSL Society, Covid-19 impact on MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Positioning Yourself to Become an MSL in 2022
Partner Avatar Bridget Rasmusson

Positioning Yourself to Become an MSL in 2022

Podcast
How Medical Affairs Professionals Should Engage with Digital Opinion Leaders
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How Medical Affairs Professionals Should Engage with Digital Opinion Leaders

Podcast
How Information is Consumed
Partner Avatar MSL Talk: Tom Caravela, Andrew Fariello

How Information is Consumed

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN